| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.007 | 0.8 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.0082 | 0.8 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.038 | 0.8 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.8 |